Evidence map›Paper›PMID 41049592›Full record

ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025

Disparate Prednisone Starting Dosages for Systemic Corticosteroid-Naïve Veterans With Active Sarcoidosis.

Nadera J Sweiss, Zane Z Elfessi, Mandeep K Sidhu, Israel Rubinstein

Abstract read
In one paragraph

Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nadera J SweissUniversity of Illinois Chicago.
Zane Z ElfessiUniversity of Illinois Chicago.
Mandeep K SidhuUniversity of Illinois Chicago.
Israel RubinsteinUniversity of Illinois Chicago.

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

Background: Sarcoidosis is a multiorgan granulomatous disorder of unknown etiology. Clinical manifestations vary and depend, in part, on the extent and severity of organ involvement. Clinical practice guidelines recommend 20 to 40 mg prednisone daily as first-line pharmacotherapy for systemic corticosteroid-naïve patients with active sarcoidosis. This study sought to determine whether initial dosages were guideline adherent. Methods: Records were restrospectively reviewed for patients diagnosed with sarcoidosis who were naïve to systemic corticosteroids and received initial prednisone dosages between 2014 and 2023 at the Jesse Brown Department of Veterans Affairs Medical Center. Patient demographics, medical specialty of the prescriber, and daily starting dosage were tabulated. Results: Sixty-eight patients were identified; most were Black (n = 52, 76%) and male (n = 62, 91%), with a mean (SD) age of 63 (11) years. Pulmonologists prescribed initial prednisone dosages in the 20 to 40 mg daily range (median, 35 mg). Other specialists, including primary care practitioners, often prescribed 20 mg (median, 17.5 mg; Conclusions: Initial prednisone dosages varied between pulmonologists and nonpulmonologists for systemic corticosteroid-naïve patients with active sarcoidosis. However, this study did not determine reasons for this phenomenon, nor its impact on long-term patient outcomes.

Identifiers

PMID41049592
PMCPMC12494339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.